Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

site via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program, R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; risks associated with the Company's dependence on corporate collaborators for development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's urocortin 2, CRF1 receptor antagonist, and VMAT2 clinical candidates will not proceed to later stage clinical trials, and risk that the Company's research programs will not identify pre-clinical candidates for further development. The Company also faces risk that the Company may be unable to obtain FDA approval for indiplon commercialization in the near future or at all. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent p
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Motionsoft, Inc. announced today that it ... (PCI) Data Security Standards (DSS) certification, making it ... in the health and wellness space that has ... is the result of a collaborative effort formed ... International, MasterCard Worldwide, American Express, Discover Financial Services ...
(Date:12/17/2009)... PHILADELPHIA, Dec. 17 The recently opened ... already out in the community in full force this ... Run on December 13th, benefiting the Arthritis Foundation, a ... of arthritis. The event boasted 1,500 attendees, spotlighting LSI,s ... Run is a renowned, national fundraiser and a festive ...
(Date:12/17/2009)... and glutathione S-transferase T1 (GSTT1) null genotypes have been ... regarding the association between GSTM1 and GSTT1 null genotypes ... However, the majority of previous reports are limited by ... GSTM1/GSTT1 null genotype with the risk of GC and ... numbers of samples. , A research article to ...
(Date:12/17/2009)... DIEGO (December 17, 2009) Researchers from the ... aim at several of the world,s most dangerous infectious ... a five-year, $18.8 million federally-funded set of projects seeking ... , The Institute received four project awards ... and Infectious Diseases (NIAID), part of the National Institutes ...
(Date:12/17/2009)... one day provide therapeutic options for muscle and bone ... the umbilical cord, just as the blood that goes ... disorders, said University of Pittsburgh School of Medicine researchers ... Journal of Biomedicine and Biotechnology . , Umbilical ... are remarkably stable and might not trigger strong immune ...
Breaking Medicine News(10 mins):Health News:Motionsoft Completes PCI Compliance Certification 2Health News:Laser Spine Institute (LSI) Supports Jingle Bell Run 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 3Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 4Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 5Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2
... to the memory and scientific accomplishments of Dr. Judah ... and shed light on the link between blood supply ... (Volume 6, Number 3-4) of Lymphatic Research and ... the research impact of one of the pre-eminent physician-scientists ...
... a child born with cleft lip and palate often have ... a normal life. For some, this year,s resolution will ... philanthropy, members of the American Society of Plastic Surgeons (ASPS) ... give than to receive," by traveling overseas on behalf of ...
... Calif., Jan. 7 The surgical lights are on, ... West Coast,s most,advanced pediatric surgery center, at Lucile Packard ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090107/AQW023 ) , ... in December, provide the,latest in imaging and communication technologies, ...
... ZMH ; SWX: ZMH) announced today it will be ... on January 13, 2009,at 12:00 p.m. Eastern Time. , ... via Zimmer,s Investor,Relations website at http://investor.zimmer.com . The webcast ... About the Company , Founded in ...
... admission PHILADELPHIA, Jan. 7 /PRNewswire/ -- ... year,s Healthy Kids Fest on Sunday, January 11, 2009, at ... to 5 p.m. Just in time for those New Year,s ... and free activities for the whole family.The Blue Cross RiverRink ...
... L.P. today announced that it has settled a lawsuit brought ... in October 2005 pertaining to Medicaid reimbursements paid by the ... a full release of claims, Dey has agreed to pay ... 2007 acquisition agreement between Mylan Inc. (Dey,s parent company) and ...
Other Medicine News:Health News:Festschrift Issue honoring Judah Folkman, M.D., in Lymphatic Research and Biology 2Health News:New year brings new hope to children born with cleft lip, palate 2Health News:Packard Children's Opens West Coast's Most Advanced Pediatric Surgery Center 2Health News:Packard Children's Opens West Coast's Most Advanced Pediatric Surgery Center 3Health News:Packard Children's Opens West Coast's Most Advanced Pediatric Surgery Center 4Health News:Families Encouraged to Enjoy Healthy Kids Fest at the Blue Cross RiverRink January 11 2Health News:Dey L.P. Settles State of Mississippi Pricing Litigation 2
(Date:12/17/2009)... Decision Resources, one of the world,s ... and healthcare issues, finds that over 70 percent ... high need for diabetes drugs with novel mechanisms ... is a high need for additional DPP-IV inhibitors. ... excellent glucose lowering ability and physicians in particular ...
(Date:12/16/2009)... Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... 2010 the U.S. Food and Drug Administration,s ... the New Drug Application (NDA) for pixantrone ... lymphoma (NHL). ODAC is an independent panel ... efficacy and safety of marketed and investigational ...
(Date:12/16/2009)... Ohio, Dec. 16 HDT Engineered Technologies ... generation technologies and a principal subcontractor for the ... led development of new anthropromorphic arm technology that ... prosthetic arm and hand, including a sense of ... Advanced Research Projects Agency (DARPA) Revolutionizing Prosthetics 2009 ...
Breaking Medicine Technology:Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2Premiere Fibers Unveils New Logo Names for Innovative Brands 49074 1Premiere Fibers Unveils New Logo Names for Innovative Brands 49074 2Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 1Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 2Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 3Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 4Torn Surgical Gloves Put Patients at Risk for Infection 49069 1Torn Surgical Gloves Put Patients at Risk for Infection 49069 2
... ... Treatment HUNTINGTON BEACH, Calif., and AMSTERDAM, ... cancer diagnostics,today announced the launch of TargetPrint(R), a new ... expression levels of,the estrogen receptor (ER), progesterone receptor (PR) ...
... and Education Foundation,s Within Our Reach Campaign Yields Significant ... ... 3 For the first time during its,unprecedented initiative to ... Research and Education Foundation is,releasing new information acquired from research ...
Other Medicine Technology:Agendia Launches TargetPrint(R) for Breast Cancer Patients 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: